Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06872359Not ApplicableActive Not Recruiting

Evaluation of Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling

Role: lead

NCT05747690Not ApplicableCompleted

Evaluation of Performance and Safety of KIO015 in Face Tissue Filling

Role: lead

NCT05214807Phase 4Unknown

Long-term Safety and Performance of KiOmedine CM-Chitosan Supplementation in Advanced Symptomatic Knee Osteoarthritis

Role: lead

NCT03679208Not ApplicableUnknown

sAfety PerfoRmance chitOsan osteOarthritis ViscosupplEmentation

Role: lead

All 4 trials loaded